Free tool
Rare disease stocks
We cover 1 company grouped under the Rare disease theme. The median market value in the group is $35.05B. Across the group, the median move over the past trading day is +0.67%. Price change over the past year runs from −46.6% to −46.6% across the middle 80 percent of the group, with a median of −46.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
1 company of 268 matches these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $35.05B | Large cap | −46.60% | Oct 29, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.